The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A 56-year-old man presented to the ED with 3 months of ...

“By dividing and conquering…we’re seeing responses in multiple different subtypes of sarcoma…and moving toward more of an individualized therapy that we try to design for every patient, where we take ...

In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...